11.97
Schlusskurs vom Vortag:
$12.03
Offen:
$12.1
24-Stunden-Volumen:
7.13M
Relative Volume:
1.53
Marktkapitalisierung:
$5.92B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$205.00M
KGV:
29.93
EPS:
0.4
Netto-Cashflow:
$372.00M
1W Leistung:
-4.01%
1M Leistung:
+0.42%
6M Leistung:
-3.86%
1J Leistung:
-25.28%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
2500 INNOVATION WAY, GREENFIELD
Vergleichen Sie ELAN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ELAN
Elanco Animal Health Inc
|
11.97 | 5.92B | 4.45B | 205.00M | 372.00M | 0.40 |
![]()
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-09 | Eingeleitet | UBS | Buy |
2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-01-05 | Hochstufung | Stifel | Hold → Buy |
2023-12-19 | Eingeleitet | Jefferies | Buy |
2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-07-21 | Herabstufung | Goldman | Buy → Sell |
2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
2021-10-28 | Herabstufung | Stifel | Buy → Hold |
2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
2021-04-15 | Eingeleitet | Stifel | Buy |
2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
2020-12-09 | Herabstufung | Argus | Buy → Hold |
2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
2020-08-04 | Fortgesetzt | Goldman | Buy |
2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-09-23 | Eingeleitet | Barclays | Overweight |
2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
2019-08-15 | Hochstufung | UBS | Sell → Neutral |
2019-05-23 | Eingeleitet | Guggenheim | Neutral |
2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
2019-01-23 | Eingeleitet | UBS | Sell |
2019-01-15 | Eingeleitet | Argus | Buy |
2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Veterinary Eye Care Market to Grow by USD 1.05 Billion(2024-2028), Boosted by Rising Pet Ownership & Market Transformation Driven by AITechnavio - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Veterinary Wound Cleansers Market Share & Growth Forecast Report 2025-2030, with Elanco, Vetoquinol, Virbac, Innovacyn, Axio Biosolutions, Neogen, Pet Natural Remedies, Zoetis and More - Yahoo Finance UK
Private Management Group Inc. Acquires 914,808 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Animal Parasiticides Market Witness Growth: Size, Share, - openPR
Elanco Launches Pradalex for Treatment of Livestock Respiratory Diseases - Drovers Magazine
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
BlackRock, Inc.'s Strategic Acquisition of Elanco Animal Health Inc Shares - GuruFocus.com
Elanco launches novel treatment for livestock respiratory diseases - Feedstuffs
Pet Pharmaceuticals Market Growth to Accelerate in Forecast - openPR
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by KBC Group NV - MarketBeat
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect - Markets Insider
Jim Cramer on Elanco Animal Health Incorporated (ELAN): ‘Not My Favorite’ - Insider Monkey
Elanco Animal Health (NYSE:ELAN) Given New $14.00 Price Target at Morgan Stanley - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Elanco Animal demitasse Health Incorporated - The Branding Iron
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
Veterinary Medicine Market Is Booming Worldwide 2025-2032 | - openPR
Elanco price target lowered to $14 from $15 at Morgan Stanley - MSN
2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
ELAN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Elanco Animal Health Incorporated and Urges Investors to Contact the Firm Today! - ACCESS Newswire
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal - PR Newswire
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Senior, geriatric dog care focus of new industry partnership - VeterinaryPracticeNews.com
Animal Gastroesophageal Reflux Disease Market Analysis Report 2025-2030, with Profiles of Key Players Zoetis, Merck, Elanco, Ceva, BioZyme, Annamaet Petfoods, Hill's Pet Nutrition, Blue Buffalo & More - Yahoo Finance
Now Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind - PR Newswire
Assenagon Asset Management S.A. Sells 1,369,833 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
2025-01-22 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out | NYSE:ELAN | Press Release - Stockhouse Publishing
Jim Cramer: AMD Is A 'Great' Company, Hold Onto Dow Inc. - Benzinga
UK Veterinary Medicine Market May See a Big Move | Norbrook, Merck, Elanco - openPR
Is Elanco Animal Health Incorporated (ELAN) the Most Undervalued Stock to Invest in for Under $20? - Insider Monkey
12 Most Undervalued Stocks to Invest in for Under $20 - Insider Monkey
Top animal health companies by revenue worldwide 2023 - Statista
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
ELAN (Elanco Animal Health) Deferred Tax : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health's SWOT analysis: stock outlook amid product challenges - MSN
ELAN (Elanco Animal Health) Long-Term Debt : $4,313 Mil (As of Sep. 2024) - GuruFocus.com
Elanco Animal Health’s SWOT analysis: stock outlook amid product challenges - Investing.com Nigeria
Companion Animal Ear Infection Treatment Market SWOT Analysis by Leading Expert: Elanco, Vetoquinol, Ceva - openPR
2025-01-15 | Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Elanco Animal Health: Building On Success (NYSE:ELAN) - Seeking Alpha
Veterinary Vaccines Market SWOT Analysis by Leading Expert: Virbac, Elanco, HIPRA - openPR
ELAN (Elanco Animal Health) Change In Working Capital : $239 Mil (TTM As of Sep. 2024) - GuruFocus.com
2025-01-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Is Elanco Animal Health (ELAN) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):